PURPOSE OF REVIEW: To review novel multiple sclerosis (MS) therapies currently in clinical trials. RECENT FINDINGS: Sixty-seven clinical trials were selected and grouped into the following categories: Bruton's tyrosine kinase inhibitors, remyelinating therapies, immunomodulators, B cell therapies, supplements/microbiome influencers, and cell-directed therapies. Important findings include tolebrutinib's successful trial in nonrelapsing secondary progressive MS that slowed CDP compared to placebo and simvastatin's failure to show an effect on disability in its phase 3 trial. SUMMARY: Multiple strategies are being investigated in MS to address progressive disability, myelin repair, neural protection and treatment refractory disease. Some of these strategies have successfully completed clinical trials giving hope that some of the most vexing aspects of MS will soon have new treatment options.

Brain and Mind Center University of Sydney Sydney New South Wales Australia

Department of Neurology Heinrich Heine University Düsseldorf Düsseldorf Germany

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Palacky University Olomouc Olomouc Czech Republic

Professor of Clinical Neurology UCSF Weill Institute for Neurosciences Department of Neurology University of California San Francisco San Francisco California USA

See more in PubMed

Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med 2020; 133:1380–1390. PubMed PMC

Selmaj K, Cree BAC, Barnett M, et al. . Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol 2024; 271:105–115. PubMed PMC

Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9:722–728. PubMed

Tsukada S, Saffran DC, Rawlings DJ, et al. . Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993; 72:279–290. PubMed

Smith CIE, Berglöf A. X-Linked Agammaglobulinemia. 2001 [updated 2024 Jun 27]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PubMed

Cool A, Nong T, Montoya S, et al. . BTK inhibitors: past, present, and future. Trends Pharmacol Sci 2024; 45:691–707. PubMed PMC

Montalban X, Arnold DL, Weber MS, et al. . Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med 2019; 380:2406–2417. PubMed

Montalban X, Vermersch P, Arnold DL, et al. . Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol 2024; 23:1119–1132. PubMed

Owens TD, Smith PF, Redfern A, et al. . Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clin Transl Sci 2022; 15:442–450. PubMed PMC

Reich DS, Arnold DL, Vermersch P, et al. . Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2021; 20:729–738. PubMed PMC

Oh J, Arnold DL, Cree BAC, et al. Efficacy and safety of tolebrutinib versus teriflunomide in relapsing multiple sclerosis: results from the phase 3 GEMINI 1 and 2 trials. Presented at ECTRIMS 2024, Abstract #O135, Copenhagen, Denmark, 18-20 September 2024.

Fox RJ, Bar-Or A, Traboulsee T, et al. Efficacy and safety of tolebrutinib versus placebo in nonrelapsing secondary progressive multiple sclerosis: results from the phase 3 HERCULES trial. Presented at ECTRIMS 2024, Abstract #O136, Copenhagen, Denmark, 18-20 September 2024.

Langlois J, Lange S, Ebeling M, et al. . Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. J Neuroinflammation 2024; 21:276. PubMed PMC

Lubetzki C, Zalc B, Williams A, et al. . Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol 2020; 19:678–688. PubMed

Cadavid D, Mellion M, Hupperts R, et al. . Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2019; 18:845–856. PubMed

Greenberg BM, Bowen JD, Alvarez E, et al. . A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse. Mult Scler J Exp Transl Clin 2022; 8:20552173221091475. PubMed PMC

Cree BAC, Cutter G, Wolinsky JS, et al. . Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2020; 19:988–997. PubMed

Brown JWL, Cunniffe NG, Prados F, et al. . Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurol 2021; 20:709–720. PubMed

Mei F, Fancy SP, Shen YA, et al. . Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med 2014; 20:954–960. PubMed PMC

Green AJ, Gelfand JM, Cree BAC, et al. . A randomized controlled double-blinded crossover trial of clemastine fumarate as a remyelinating therapy for multiple sclerosis. Lancet 2017; 390:2481–2489. PubMed

Robinson AP, Zhang JZ, Titus HE, et al. . Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci Rep 2020; 10:1936. PubMed PMC

Ren J, Dewey RB, 3rd, Rynders A, et al. . Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials. J Nanobiotechnology 2023; 21:478. PubMed PMC

Muehler A, Peelen E, Kohlhof H, et al. . Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2020; 43:102129. PubMed

Fox RJ, Wiendl H, Wolf C, et al. . Safety and dose-response of Vidofludimus calcium in relapsing multiple sclerosis: extended results of a placebo-controlled Phase 2 trial. Neurol Neuroimmunol Neuroinflamm 2024; 11:e200208. PubMed PMC

Vermersch P, Benrabah R, Schmidt N, et al. . Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol 2012; 12:36. PubMed PMC

Vermersch P, Brieva-Ruiz L, Fox RJ, et al. . Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, Phase 3, clinical trial. Neurol Neuroimmunol Neuroinflamm 2022; 9:e1148. PubMed PMC

Fadul CE, Mao-Draayer Y, Ryan KA, et al. . Safety and immune effects of blocking CD40 ligand in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2021; 8:e1096. PubMed PMC

Kawai T, Andrews D, Colvin RB, et al. . Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6:114–1114. PubMed

Vermersch P, Granziera C, Mao-Draayer Y, et al. . Inhibition of CD40L with frexalimab in multiple sclerosis. N Engl J Med 2024; 390:589–600. PubMed

Abdalla MA, Zakhary CM, Rushdi H, et al. . The effectiveness of statins as potential therapy for multiple sclerosis: a systematic review of randomized controlled trials. Cureus 2021; 13:e18092. PubMed PMC

Chataway J, Schuerer N, Alsanousi A, et al. . Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebocontrolled, phase 2 trial. Lancet 2014; 383:2213–2221. PubMed

Chataway J, Williams T, Blackstone J, et al. . Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2 trial): a multicentre, randomised placebo-controlled, double-blind, phase 3 clinical trial. Presented at ECTRIMS 2024; Abstract #O134, Copenhagen, Denmark, 18-20 September 2024.18-20 September 2024. PubMed PMC

Comi G, Bar-Or A, Lassmann H, et al. . Role of B cells in multiple sclerosis and related disorders. Ann Neurol 2021; 89:13–23. PubMed PMC

J. Chang WY, Ma YL, Chambers MG, et al. . A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight 2023; 8:e166137. PubMed PMC

Perugino CA, Wallace ZS, Zack DJ, et al. . Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial. Lancet Rheumatol 2023; 5:e442–e450. PubMed

Merrill JT, Guthridge J, Smith M, et al. . Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, Phase 2 trial. Arthritis Rheumatol 2023; 75:2185–2194. PubMed

Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc) 2022; 58:23–32. PubMed

Juszczak E, Altman DG, Hopewell S, et al. . Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 Statement. JAMA 2019; 321:1610–1620. PubMed

iMSMS Consortium. Electronic address: sergio.baranzini@ucsf.edu; iMSMS Consortium. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022; 185:3467–3486.e16. PubMed PMC

Pröbstel AK, Baranzini SE. Neurotherapeutics the role of the gut microbiome in multiple sclerosis risk and progression: towards characterization of the “MS Microbiome”. Neurotherapeutics 2018; 15:126–134. PubMed PMC

Thouvenot E, Laplaud D, Lebrun-Frenay C, et al. . High-dose cholecalciferol reduces multiple sclerosis disease activity after a clinically isolated syndrome: results of a 24-month placebo-controlled randomized trial (D-lay MS). Presented at ECTRIMS 2024; Abstract #O065, Copenhagen, Denmark, 18-20 September 2024.

Alexander T, Sharrack B, Saccardi R, et al. . Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant 2020; 55:283–306. PubMed PMC

Müller F, Taubmann J, Bucci L, et al. . CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med 2024; 390:687–700. PubMed

Ismail FS, Gallus M, Meuth SG, et al. . Current and future roles of chimeric antigen receptor T-cell therapy in neurology: a review. JAMA Neurol 2025; 82:93–103. PubMed

Pfeffer LK, Fischbach F, Heesen C, Friese MA. Current state and perspectives of CAR T cell therapy in central nervous system diseases. Brain 2025; 148:723–736. PubMed

Ellithi M, Elsallab M, Lunning MA, et al. . Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS Data. Transplant Cell Ther 2024; S2666-6367:00803-0. PubMed